Information Provided By: 
Fly News Breaks for June 11, 2019
RVNC
Jun 11, 2019 | 05:57 EDT
Barclays analyst Balaji Prasad started Revance Therapeutics with an Overweight rating and $28 price target. The analyst launched coverage of 20 U.S. Specialty Pharmaceuticals with a Neutral industry view. He placed importance on cash flows and companies' ability to manage leverage and improve balance sheets.
News For RVNC From the Last 2 Days
There are no results for your query RVNC
